Every cancer patient deserves to know what trials exist for them

ClinicalTrials.gov lists all trials but offers no biomarker filtering. You get hundreds of results regardless of eligibility. OncoMatch reads your EGFR, ALK, KRAS, BRAF, HER2, BRCA1/2, MSI-H, PD-L1, and other biomarker results and filters down to trials designed for your specific cancer profile.

Biomarkers are genetic mutations, proteins, or other molecular features found in your tumor. Most modern oncology trials target specific biomarkers. A trial for BRAF-positive melanoma only enrolls patients who have that mutation. Matching on biomarkers is what separates relevant trials from irrelevant ones.

OncoMatch supports the major targeted therapy and immunotherapy markers used in oncology, including: EGFR (exon 19 deletion, L858R, exon 20 insertion, and others), ALK, KRAS (including G12C), BRAF, HER2/ERBB2, RET, NTRK1/2/3, MET, ROS1, BRCA1/2, PALB2, ATM, CHEK2, MSI-H/dMMR, PD-L1, TMB, IDH1/2, FLT3 (including ITD), PIK3CA, ESR1, FGFR1/2/3, and more. The specific panel shown depends on your cancer type — lung cancer shows EGFR, ALK, KRAS, RET, MET, ROS1, and NTRK; breast shows HER2, BRCA1/2, PIK3CA, and ESR1; and so on. You can also enter any gene manually.

No. You can search by cancer type alone and see all available trials. If you add biomarker results, we filter further and mark which trials require testing you haven't done yet, so you know what to ask your oncologist about.

Yes. Many trials are specifically designed for advanced or metastatic disease. In fact, Stage IV patients are often the primary population in Phase 2 and Phase 3 oncology trials, because those trials test treatments in patients who have already exhausted earlier options. Enter your cancer type and stage to see what's available.

EGFR (Epidermal Growth Factor Receptor) is a protein that, when mutated, drives tumor growth in some lung and other cancers. If your pathology report shows an EGFR mutation (such as exon 19 deletion or L858R), you may be eligible for targeted therapy trials that specifically require that mutation. OncoMatch filters for EGFR-positive trials automatically when you enter your result.

MSI-H (microsatellite instability-high) is a marker of DNA mismatch repair deficiency found in some colorectal, endometrial, and other cancers. It is a strong predictor of response to immunotherapy, particularly pembrolizumab (Keytruda). Many immunotherapy trials require MSI-H status. If your report mentions 'MSI-H', 'dMMR', or 'mismatch repair deficient', mark that biomarker in OncoMatch to find relevant trials.

PD-L1 (Programmed Death-Ligand 1) is a protein measured as a percentage of tumor cells staining positive. High PD-L1 expression (e.g., ≥50%) often predicts better response to checkpoint inhibitor drugs. Many immunotherapy trials set a minimum PD-L1 score as an eligibility criterion. Enter your PD-L1 percentage in OncoMatch and we'll filter trials accordingly.

Once you run a search, use the 'Share with doctor' button in the results bar. This opens your browser's print dialog. You can save as a PDF or print directly. The output is formatted as a clean handout: your cancer profile at the top, then your top-matching trials with NCT IDs your oncologist or nurse coordinator can look up immediately.

Yes. Enter your zip code or city and OncoMatch will show the distance to the nearest trial site for each result. Many trials have multiple sites. A trial based at a large academic center may also run at a community hospital closer to you. Distance is shown for every result so you can decide what's feasible.

Usually not. Most clinical trials cover the cost of the experimental treatment and related study visits. Routine care costs may still apply depending on your insurance. OncoMatch itself is always free to use.

Recruiting means the trial is actively enrolling new patients right now. All trials shown in OncoMatch are in recruiting status. Trials that have stopped enrollment are excluded from results.

Phase 1 trials are primarily safety studies, often in patients with advanced or refractory disease who have exhausted other options — small groups, dose-finding, may still offer benefit. Phase 2 trials test whether a treatment works and assess side effects, typically in dozens to a few hundred patients. Phase 3 trials compare the new treatment to standard care in larger groups to confirm effectiveness and safety. Phase 4 trials study an already-approved treatment in broader populations. OncoMatch includes all phases — which is right for you depends on your situation and your oncologist's guidance.

Yes. Some trials specifically want treatment-naive patients (no prior therapy). You can filter by prior treatment status to find these. Your oncologist can advise whether joining a trial before standard treatment makes sense for your case.

Trial data is sourced from the AACT database (Aggregate Analysis of ClinicalTrials.gov), which mirrors ClinicalTrials.gov and is updated daily. Eligibility criteria are extracted and structured by AI to enable biomarker filtering.